Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Lupus Nephritis Market Growth in 2025?

In recent times, the lupus nephritis market has seen robust growth. The expansion is predicted to escalate from a worth of $1.94 billion in 2024 to approximately $2.09 billion in 2025, with a compound annual growth rate (CAGR) of 7.9%. The growth experienced in the past years can be traced back to increased funding in lupus nephritis research, growing occurrences of autoimmune diseases, a rise in healthcare spending, heightened use of biologics, and the surging popularity of telemedicine.

What Is the Forecast for the Lupus Nephritis Market Size Through 2029?

The market size for lupus nephritis is anticipated to witness substantial expansion in the upcoming years, reaching a valuation of $2.80 billion in 2029, growing at a compound annual growth rate (CAGR) of 7.6%. Factors that could contribute to this growth during the forecast period include heightened awareness among physicians, a rise in the use of biologic therapies, growth in the number of specialty clinics, heightened focus on renal transplantation, and improved access to nephrologist services. Prominent trends during the forecast period are likely to be developments in biologic therapies, bespoke medicine strategies, innovative diagnostic biomarkers, the broadening of clinical trials, and progress in stem cell therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

What are the Key Market Players in Lupus Nephritis Market and How They’re Evolving?

Major companies operating in the lupus nephritis market are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Genentech, Astrazeneca PLC, Biocon Biologics, Hanmi Pharmaceutical Co. Ltd., Sana Biotechnology Inc., RemeGen Co. Ltd., Aurinia Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Equillium Inc., Anthera Pharmaceuticals Inc., Atara Biotherapeutics Inc., Artiva Biotherapeutics, Caribou Biosciences, Nkarta Inc., Adicet Bio Inc., Lupus Research Alliance, Kyverna Therapeutics Inc., Kezar Life Sciences, Bionxt Solutions.

What Are the Primary Growth Drivers in the Lupus Nephritis Market?

The growing occurrence of genetic predisposition is believed to spur the expansion of the lupus nephritis market in the future. Genetic predisposition relates to the genetic characteristics one inherits that heighten their chances of developing particular diseases or health-related issues. This rise in genetic predisposition is a result of various factors such as hereditary patterns, environmental impacts, and mutations in certain genes. This surge of genetic predisposition significantly influences the development of lupus nephritis, highlighting the integral role of inherited genetics in autoimmune disorders, particularly those impacting kidney functions. As an example, the UK CF Registry, managed by the Cystic Fibrosis Trust, a national charity in the UK, recorded 11,148 registered patients in 2022. In 2024, this number rose to 11,318, indicating a 1.52% rise in individuals with cystic fibrosis (CF). Consequently, the growing occurrence of genetic predisposition is propelling the expansion of the lupus nephritis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22044&type=smp

What Are the Leading Segments in the Global Lupus Nephritis Industry?

The lupus nephritis market covered in this report is segmented –

1) By Stage: Class 1, Class 2, Class 3, Other Stages

2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs

3) Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis.

2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition.

3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation.

4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

What Are the Key Market Trends in the Lupus Nephritis Industry?

Preeminent firms in the lupus nephritis market are concentrating on advancing second-generation calcineurin inhibitors to augment the effectiveness of treatment and elevate long-term kidney results for patients. By modulating immune responses, these inhibitors play a significant role in lupus nephritis, reducing inflammation and averting kidney damage. For instance, in September 2024, Aurinia Pharmaceuticals Inc, a commercially active biopharmaceutical company from Canada, received approval from the Japanese Ministry of Health, Labour, and Welfare for the use of LUPKYNIS (voclosporin) in the treatment of lupus nephritis. The approval, based on supporting data from the AURORA Clinical Program, confirms its safety and efficacy, and allows it to be used with mycophenolate mofetil (MMF). This approval signifies a crucial progression in increasing treatment choices for patients with lupus nephritis in Japan, thus enhancing disease control and results.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

What Is the Regional Outlook for the Lupus Nephritis Market?

Asia-Pacific was the largest region in the lupus nephritis market in 2024. The regions covered in the lupus nephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22044

This Report Delivers Insight On:

1. How big is the lupus nephritis market, and how is it changing globally?

2. Who are the major companies in the lupus nephritis market, and how are they performing?

3. What are the key opportunities and risks in the lupus nephritis market right now?

4. Which products or customer segments are growing the most in the lupus nephritis market?

5. What factors are helping or slowing down the growth of the lupus nephritis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model